Royal Bank of Canada
BOLT icon

Royal Bank of Canada’s Bolt Biotherapeutics BOLT Stock Holding History

Royal Bank of Canada’s Portfolio BOLT Stock Details BOLT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-18
Closed – – 6871
2024
Q2 		$0 Buy
+18
New +$355 ﹤0.01% 7069
2024
Q1 		– Sell
-23
Closed -$533 – 7028
2023
Q4 		$0 Buy
23
+18
+360% +$350 ﹤0.01% 7129
2023
Q3 		$0 Buy
+5
New +$122 ﹤0.01% 7090
2022
Q3 		– Sell
-50
Closed -$2K – 7451
2022
Q2 		$2K Sell
50
-20
-29% -$776 ﹤0.01% 6921
2022
Q1 		$4K Sell
70
-159
-69% -$10.7K ﹤0.01% 7306
2021
Q4 		$22K Buy
229
+107
+88% +$20.3K ﹤0.01% 6757
2021
Q3 		$31K Buy
122
+82
+205% +$23.2K ﹤0.01% 6439
2021
Q2 		$12K Sell
40
-19
-32% -$7.71K ﹤0.01% 6797
2021
Q1 		$39K Buy
+59
New +$38.4K ﹤0.01% 6036

Other funds holding BOLT

TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
PBPIA
Pivotal bioVenture Partners Investment Advisor San Francisco, California $280M AUM 181.4% 1-Year Est. Return
NFGH
Nan Fung Group Holdings Kai Tak, Hong Kong $121M AUM 56.89% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
BOTOTLSJU
Board of Trustees of The Leland Stanford Junior University Redwood City, California $849M AUM 55.45% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
NM
Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return

Royal Bank of Canada's BOLT Position: Q3 2024 in Review

Royal Bank of Canada sold out of Bolt Biotherapeutics (BOLT) in Q3 2024, closing a stake of 18 shares.

Royal Bank of Canada first reported a position in BOLT in Q1 2021 and held it in 9 quarters. The position peaked at $39K in Q1 2021. 32 funds tracked by Wall St. Rank hold BOLT as of Q3 2024.

  • Royal Bank of Canada reported no remaining Bolt Biotherapeutics position as of Q3 2024 after selling out during the quarter.
  • Royal Bank of Canada sold 18 Bolt Biotherapeutics shares in Q3 2024.
  • Royal Bank of Canada first reported a position in Bolt Biotherapeutics in Q1 2021 and held it in 9 quarters.
  • Royal Bank of Canada's Bolt Biotherapeutics position peaked at $39K in Q1 2021.
  • 32 funds tracked by Wall St. Rank held Bolt Biotherapeutics as of Q3 2024.

Based on Royal Bank of Canada's 13F filing for Q3 2024, filed 14 Nov 2024.